Profile image
Story Views

Last Hour:
Last 24 Hours:

Arterial Thrombosis Treatment Pipeline Review H2 2016

Monday, October 17, 2016 0:51
% of readers think this story is Fact. Add your two cents.

(Before It's News)


 ‘Arterial Thrombosis – Pipeline Review, H2 2016’, provides an overview of the Arterial Thrombosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @


- The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis
- The report reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Arterial Thrombosis therapeutics and enlists all their major and minor projects
- The report assesses Arterial Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Arterial Thrombosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Arterial Thrombosis Overview 7
Therapeutics Development 8
Pipeline Products for Arterial Thrombosis – Overview 8
Pipeline Products for Arterial Thrombosis – Comparative Analysis 9
Arterial Thrombosis – Therapeutics under Development by Companies 10
Arterial Thrombosis – Therapeutics under Investigation by Universities/Institutes 11
Arterial Thrombosis – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Arterial Thrombosis – Products under Development by Companies 15
Arterial Thrombosis – Products under Investigation by Universities/Institutes 16
Arterial Thrombosis – Companies Involved in Therapeutics Development 17
Astellas Pharma Inc. 17
AstraZeneca Plc 18
Bayer AG 19
Bristol-Myers Squibb Company 20
Eisai Co., Ltd. 21
Johnson & Johnson 22
Sanofi 23
Thromboserin Ltd 24
TSRL, Inc. 25
Arterial Thrombosis – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AS-1468240 – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ASP-6537 – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BAY-1213790 – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BMS-593214 – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BMS-654457 – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
C-3 – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
E-5539 – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ER-410660 – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
FM-19 – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
JNJ-375 – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
PZ-128 – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
SAR-216471 – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
THL-001 – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ticagrelor – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Arterial Thrombosis – Dormant Projects 57
Arterial Thrombosis – Product Development Milestones 58
Featured News & Press Releases 58
Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

Buy this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.